Statement of Deviation and Variation for the quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Venmax Drugs and Pharmaceuticals has filed a quarterly compliance statement confirming there is no deviation or variation in the use of funds raised through a preferential issue of fully convertible equity warrants. The total preferential issue size is Rs. 20.05 crores, of which Rs. 5.54 crores has been received from the conversion of 27.69 lakh warrants, and an additional Rs. 4.45 crores has been received against 72.56 lakh share warrants awaiting conversion. Of the allocated funds, Rs. 3.79 crores has been utilized for Working Capital (out of Rs. 10 crores earmarked) and Rs. 0.19 crores for General Corporate Purpose and Business Acquisition (out of Rs. 10.05 crores earmarked) as of December 31, 2025. The Audit Committee reviewed and confirmed compliance with the original objects stated in the EGM notice on February 7, 2026.
This is a routine SEBI compliance filing (Reg 32) confirming funds are being deployed as originally disclosed to shareholders. No negative impact on the stock; however, the slow utilization rate (only Rs. 3.98 crores of the Rs. 9.99 crores actually received deployed so far) is worth noting for investors monitoring capital efficiency.